Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension

American Journal of Respiratory Cell and Molecular Biology

Volumn 49, Issue 5, 2013, Pages 778-787

  Fessel, Joshua P ^a   Flynn, Charles R ^a   Robinson, Linda J ^a   Penner, Niki L ^a   Gladson, Santhi ^a   Kang, Christie J ^a   Wasserman, David H ^b   Hemnes, Anna R ^a   West, James D ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bmpr2; Hyperoxia; Mitochondria; Oxidative stress; Pulmonary hypertension

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; GLUCOSE; REACTIVE OXYGEN METABOLITE;

AMBIENT AIR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GLUCOSE BLOOD LEVEL; HEART OUTPUT; HYPEROXIA; LIPID PEROXIDATION; LUNG CIRCULATION; METABOLIC STRESS; MICROVASCULAR ENDOTHELIAL CELL; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONCENTRATION; PHENOTYPE; PROTEIN EXPRESSION; PULMONARY ARTERY OCCLUSION; PULMONARY HYPERTENSION; VASODILATATION;

ANIMALS; ARTERIAL PRESSURE; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CARDIAC OUTPUT; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HUMANS; HYPEROXIA; HYPERTENSION, PULMONARY; LUNG; LUNG INJURY; MICE; MICE, TRANSGENIC; MITOCHONDRIA; MITOCHONDRIAL MEMBRANES; MUTATION; OXIDATIVE STRESS; PULMONARY ARTERY; REACTIVE OXYGEN SPECIES; STRESS, PHYSIOLOGICAL; VENTRICULAR FUNCTION, RIGHT; VENTRICULAR PRESSURE;

EID: 84887080883     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0463OC     Document Type: Article

References (50)

1. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003;361: 1533-1544.
2. Tuder RM, Abman SH, Braun T, Capron F, Stevens T, Thistlethwaite PA, Haworth SG. Development and pathology of pulmonary hypertension. J Am Coll Cardiol 2009;54 (Suppl. 1)S3-S9.
3. Jurasz P, Courtman D, Babaie S, Stewart DJ. Role of apoptosis in pulmonary hypertension: from experimental models to clinical trials. Pharmacol Ther 2010;126: 1-8.
4. Archer SL, Gomberg-Maitland M, Maitland ML, Rich S, Garcia JG, Weir EK. Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF- 1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol 2008;294:H570-H578.
5. Mingatto FE, Maioli MA, Bracht A, Ishii-Iwamoto EL. Effects of monocrotaline on energy metabolism in the rat liver. Toxicol Lett 2008;182: 115-120.
6. Rehman J, Archer SL. A proposed mitochondrial-metabolic mechanism for initiation and maintenance of pulmonary arterial hypertension in Fawn-Hooded rats: the Warburg model of pulmonary arterial hypertension. Adv Exp Med Biol 2010;661: 171-185.
7. Xu W, Koeck T, Lara AR, Neumann D, DiFilippo FP, Koo M, Janocha AJ, Masri FA, Arroliga AC, Jennings C, et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci USA 2007;104: 1342-1347.
8. Demarco VG, Whaley-Connell AT, Sowers JR, Habibi J, Dellsperger KC. Contribution of oxidative stress to pulmonary arterial hypertension. World J Cardiol 2010;2: 316-324.
9. Lane KL, TalatiM, Austin E, Hemnes AR, Johnson JA, Fessel JP, Blackwell T, Mernaugh RL, Robinson L, Fike C, et al. Oxidative injury is a common consequence of Bmpr2 mutations. Pulm Circ 2011;1: 72-83.
10. Cracowski JL, Degano B, Chabot F, Labarère J, Schwedhelm E, Monneret D, Iuliano L, Schwebel C, Chaouat A, Reynaud-Gaubert M, et al. Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension. Chest 2012;142: 869-876.
11. Guignabert C, Tu L, Izikki M, Dewachter L, Zadigue P, Humbert M, Adnot S, Fadel E, Eddahibi S. Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alphatargeted overexpression of the serotonin transporter. FASEB J 2009;23: 4135-4147.
12. Michelakis ED, McMurtry MS, Wu XC, Dyck JR, Moudgil R, Hopkins TA, Lopaschuk GD, Puttagunta L, Waite R, Archer SL. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltagegated potassium channels. Circulation 2002;105: 244-250.
13. Jerkic M, Kabir MG, Davies A, Yu LX, McIntyre BA, Husain NW, Enomoto M, Sotov V, Husain M, Henkelman M, et al. Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress. Cardiovasc Res 2011;92: 375-384.
14. Kamezaki F, Tasaki H, Yamashita K, Tsutsui M, Koide S, Nakata S, Tanimoto A, Okazaki M, Sasaguri Y, Adachi T, et al. Gene transfer of extracellular superoxide dismutase ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2008;177: 219-226.
15. Archer SL, Marsboom G, Kim GH, Zhang HJ, Toth PT, Svensson EC, Dyck JR, Gomberg-Maitland M, Thébaud B, Husain AN, et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 2010;121: 2661-2671.
16. Hansmann G, Zamanian RT. PPARgamma activation: a potential treatment for pulmonary hypertension. Sci Transl Med 2009;1: 12ps14.
17. Pugh ME, Hemnes AR. Metabolic and hormonal derangements in pulmonary hypertension: from mouse to man. Int J Clin Pract 2010;168 (Suppl.): 5-13.
18. Hansmann G, de Jesus Perez VA, Alastalo TP, Alvira CM, Guignabert C, Bekker JM, Schellong S, Urashima T, Wang L, Morrell NW, et al. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 2008;118: 1846-1857.
19. Crossno JT Jr, Garat CV, Reusch JE, Morris KG, Dempsey EC, McMurtry IF, Stenmark KR, Klemm DJ. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol 2007;292:L885-L897.
20. Pugh ME, Robbins IM, Rice TW, West J, Newman JH, Hemnes AR. Unrecognized glucose intolerance is common in pulmonary arterial hypertension. J Heart Lung Transplant 2011;30: 904-911.
21. Yusa T, Crapo JD, Freeman BA. Hyperoxia enhances lung and liver nuclear superoxide generation. Biochim Biophys Acta 1984;798: 167-174.
22. Freeman BA, Young SL, Crapo JD. Liposome-mediated augmentation of superoxide dismutase in endothelial cells prevents oxygen injury. J Biol Chem 1983;258: 12534-12542.
23. Turrens JF, Freeman BA, Levitt JG, Crapo JD. The effect of hyperoxia on superoxide production by lung submitochondrial particles. Arch Biochem Biophys 1982;217: 401-410.
24. Freeman BA, Topolosky MK, Crapo JD. Hyperoxia increases oxygen radical production in rat lung homogenates. Arch Biochem Biophys 1982;216: 477-484.
25. Fessel JP, Flynn CR, Robinson LJ, West J. Mitochondrial oxidative stress driven by hyperoxia plays a causative role in Bmpr2-mediated pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;185: A1253.
26. Johnson JA, Hemnes AR, Perrien DS, Schuster M, Robinson LJ, Gladson S, Loibner H, Bai S, Blackwell TR, Tada Y, et al. Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2012;302:L474-L484.
27. Darley-Usmar VM, Rickwood D, Wilson MT. Mitochondria: a practical approach, 1st ed. Oxford: IRL Press; 1987. p. 340.
28. Fessel JP, Porter NA, Moore KP, Sheller JR, Roberts LJ II. Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. Proc Natl Acad Sci USA 2002;99: 16713-16718.
29. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ II. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990;87: 9383-9387.
30. West J, Niswender KD, Johnson JA, Pugh ME, Gleaves L, Fessel JP, Hemnes AR. A potential role for insulin resistance in experimental pulmonary hypertension. Eur Respir J 2013;41: 861-871.
31. Majka S, Hagen M, Blackwell T, Harral J, Johnson JA, Gendron R, Paradis H, Crona D, Loyd JE, Nozik-Grayck E, et al. Physiologic and molecular consequences of endothelial Bmpr2 mutation. Respir Res 2011;12: 84.
32. Fessel JP, Hulette C, Powell S, Roberts LJ II, Zhang J. Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. J Neurochem 2003;85: 645-650.
33. Roberts LJ II, Fessel JP. The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Chem Phys Lipids 2004;128: 173-186.
34. Fessel JP, Jackson Roberts L. Isofurans: novel products of lipid peroxidation that define the occurrence of oxidant injury in settings of elevated oxygen tension. Antioxid Redox Signal 2005;7: 202-209.
35. Patel M, Liang LP, Hou H, Williams BB, Kmiec M, Swartz HM, Fessel JP, Roberts LJ II. Seizure-induced formation of isofurans: novel products of lipid peroxidation whose formation is positively modulated by oxygen tension. J Neurochem 2008;104: 264-270.
36. Dromparis P, Sutendra G, Michelakis ED. The role of mitochondria in pulmonary vascular remodeling. J Mol Med (Berl) 2010;88: 1003-1010.
37. Tuder RM, Davis LA, Graham BB. Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension. Am J Respir Crit Care Med 2012;185: 260-266.
38. Zamanian RT, Hansmann G, Snook S, Lilienfeld D, Rappaport KM, Reaven GM, Rabinovitch M, Doyle RL. Insulin resistance in pulmonary arterial hypertension. Eur Respir J 2009;33: 318-324.
39. Marsboom G, Wietholt C, Haney CR, Toth PT, Ryan JJ, Morrow E, Thenappan T, Bache-Wiig P, Piao L, Paul J, et al. Lung 1jFfluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;185: 670-679.
40. Hagan G, Southwood M, Treacy C, Ross RM, Soon E, Coulson J, Sheares K, Screaton N, Pepke-Zaba J, Morrell NW, et al. (18)FDG PET imaging can quantify increased cellular metabolism in pulmonary arterial hypertension: a proof-of-principle study. Pulm Circ 2011;1: 448-455.
41. Lambert CM, Roy M, Robitaille GA, Richard DE, Bonnet S. HIF-1 inhibition decreases systemic vascular remodelling diseases by promoting apoptosis through a hexokinase 2-dependent mechanism. Cardiovasc Res 2010;88: 196-204.
42. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, et al.Amitochondria- K1 channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007;11: 37-51.
43. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thébaud B, Bonnet S, Haromy A, Harry G, Moudgil R, McMurtry MS, et al. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in Fawn Hooded rats: similarities to human pulmonary arterial hypertension. Circulation 2006;113: 2630-2641.
44. Sutendra G, Dromparis P, Wright P, Bonnet S, Haromy A, Hao Z, McMurtry MS, Michalak M, Vance JE, Sessa WC, et al. The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension. Sci Transl Med 2011;3: 88ra55.
45. Marsboom G, Toth PT, Ryan JJ, Hong Z, Wu X, Fang YH, Thenappan T, Piao L, Zhang HJ, Pogoriler J, et al. Dynamin-related protein 1- mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res 2012;110: 1484-1497.
46. Fessel JP, Hamid R, Wittmann BM, Robinson LJ, Blackwell T, Tada Y, Tanabe N, Tatsumi K, Hemnes AR, West JD. Metabolomic analysis of bone morphogenetic protein receptor Type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming. Pulm Circ 2012;2: 201-213.
47. Scatena R, Messana I, Martorana GE, Gozzo ML, Lippa S, Maccaglia A, Bottoni P, Vincenzoni F, Nocca G, Castagnola M, et al. Mitochondrial damage and metabolic compensatory mechanisms induced by hyperoxia in the U-937 cell line. J Biochem Mol Biol 2004;37: 454-459.
48. Allen CB, Guo XL, White CW. Changes in pulmonary expression of hexokinase and glucose transporter mRNAs in rats adapted to hyperoxia. Am J Physiol 1998;274:L320-L329.
49. Clapham JC, Arch JR, Chapman H, Haynes A, Lister C, Moore GB, Piercy V, Carter SA, Lehner I, Smith SA, et al. Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean. Nature 2000;406: 415-418.
50. Mark AL, Sivitz WI. Uncoupling metabolism and coupling leptin to cardiovascular disease. Arterioscler Thromb Vasc Biol 2002;22: 881-883.